相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects
Jerold Chun et al.
DRUGS (2021)
Novel compounds with dual S1P receptor agonist and histamine H3 receptor antaglonist activities act protective in a mouse model of multiple sclerosis
Faik Imeri et al.
NEUROPHARMACOLOGY (2021)
Suppressive Effect of CYM50358 S1P4 Antagonist on Mast Cell Degranulation and Allergic Asthma in Mice
Wi-Jin Jeon et al.
BIOMOLECULES & THERAPEUTICS (2021)
Absorption, Metabolism, and Excretion, In Vitro Pharmacology, and Clinical Pharmacokinetics of Ozanimod, a Novel Sphingosine 1-Phosphate Receptor Modulator
Sekhar Surapaneni et al.
DRUG METABOLISM AND DISPOSITION (2021)
Loss of sphingosine kinase 2 enhances Wilm's tumor suppressor gene 1 and nephrin expression in podocytes and protects from streptozotocin-induced podocytopathy and albuminuria in mice
Faik Imeri et al.
MATRIX BIOLOGY (2021)
Targeting the S1P receptor signaling pathways as a promising approach for treatment of autoimmune and inflammatory diseases
Bisera Stepanovska et al.
PHARMACOLOGICAL RESEARCH (2020)
Downregulation of S1P Lyase Improves Barrier Function in Human Cerebral Microvascular Endothelial Cells Following an Inflammatory Challenge
Bisera Stepanovska et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Morpholino Analogues of Fingolimod as Novel and Selective S1P1 Ligands with In Vivo Efficacy in a Mouse Model of Experimental Antigen-Induced Encephalomyelitis
Bisera Stepanovska et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Cenerimod Sphingosine 1-phosphate receptor 1 (S1P1) agonist Treatment of systemic lupus erythematosus
B. Stepanovska Tanturovska et al.
DRUGS OF THE FUTURE (2020)
Amiselimod (MT-1303), a Novel Sphingosine 1-Phosphate Receptor-1 Modulator, Potently Inhibits the Progression of Lupus Nephritis in Two Murine SLE Models
Kunio Sugahara et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2019)
Internalization of G-protein-coupled receptors: Implication in receptor function, physiology and diseases
Davide Calebiro et al.
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2018)
Abnormal islet sphingolipid metabolism in type 1 diabetes
Laurits J. Holm et al.
DIABETOLOGIA (2018)
The sphingosine 1-phosphate receptor modulator fingolimod as a therapeutic agent: Recent findings and new perspectives
Andrea Huwiler et al.
PHARMACOLOGY & THERAPEUTICS (2018)
Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity
F. L. Scott et al.
BRITISH JOURNAL OF PHARMACOLOGY (2016)
Sphingosine kinase 2 deficient mice exhibit reduced experimental autoimmune encephalomyelitis: Resistance to FTY720 but not ST-968 treatments
Faik Imeri et al.
NEUROPHARMACOLOGY (2016)
Lysophospholipid receptor nomenclature review: IUPHAR Review 8
Yasuyuki Kihara et al.
BRITISH JOURNAL OF PHARMACOLOGY (2014)
Novel oxazolo-oxazole derivatives of FTY720 reduce endothelial cell permeability, immune cell chemotaxis and symptoms of experimental autoimmune encephalomyelitis in mice
Faik Imeri et al.
NEUROPHARMACOLOGY (2014)
Desensitization by Progressive Up-Titration Prevents First-Dose Effects on the Heart: Guinea Pig Study with Ponesimod, a Selective S1P1 Receptor Modulator
Markus Rey et al.
PLOS ONE (2013)
The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate
P. Gergely et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis
M. Mehling et al.
NEUROLOGY (2011)
Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis
Volker Brinkmann et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Efficient chromatography-free synthesis of the oxy-analogue of fingolimod
Aleksandra Zivkovic et al.
TETRAHEDRON LETTERS (2010)
Update of the LIPID MAPS comprehensive classification system for lipids
Eoin Fahy et al.
JOURNAL OF LIPID RESEARCH (2009)
Improving physical realism, stereochemistry, and side-chain accuracy in homology modeling: Four approaches that performed well in CASP8
Elmar Krieger et al.
PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS (2009)
New players on the center stage: Sphingosine 1-phosphate and its receptors as drug targets
Andrea Huwiler et al.
BIOCHEMICAL PHARMACOLOGY (2008)
The alliance of sphingosine-1-phosphate and its receptors in immunity
Juan Rivera et al.
NATURE REVIEWS IMMUNOLOGY (2008)
Sphingosine 1-phosphate receptors in health and disease: Mechanistic insights from gene deletion studies and reverse pharmacology
Volker Brinkmann
PHARMACOLOGY & THERAPEUTICS (2007)
S1P1-selective in vivo-active agonists from high-throughput screening:: Off-the-shelf chemical probes of receptor interactions, signaling, and fate
EJ Jo et al.
CHEMISTRY & BIOLOGY (2005)
A comprehensive classification system for lipids
E Fahy et al.
JOURNAL OF LIPID RESEARCH (2005)
LigandScout: 3-d pharmacophores derived from protein-bound Ligands and their use as virtual screening filters
G Wolber et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2005)
FTY720: Sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function
V Brinkmann et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2004)
The immune modulator FTY720 targets sphingosine 1-phosphate receptors
V Brinkmann et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists
S Mandala et al.
SCIENCE (2002)
分享论文
